Navigation Links
Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
Date:4/28/2008

SHELTON, Conn., April 28 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 58 healthy male and female volunteers.

The company is also developing oral and subcutaneous formulations of CR845.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibits analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus) or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward- looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
6. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
9. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... ...
(Date:1/13/2017)... , January 13, 2017 Stock-Callers is ... Medical Group N.V. (NASDAQ: WMGI ), Varian Medical ... (NASDAQ: MDXG ), and NuVasive Inc. (NASDAQ: ... which fell back to a negative finish on Thursday, January ... falling about 0.1%, while shares of health care companies in ...
(Date:1/13/2017)...  Alfalfa, cattle, leafy greens and rosy cheeked children share ... which emphasizes the food industry,s shift from response to prevention. ... COPAN,s Swab Rinse Kit (SRK™) is ... in the wake of the new FDA Food Safety ... is expanding the U.S. production of the SRK line ...
Breaking Medicine Technology:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
(Date:1/15/2017)... ... 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version of ... purchase. , The 2017 edition has wide jaws that will accommodate nails up to ... well as diabetics. This handle is reinforced for extra strength when pressing down on dense ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music ... customization and ease," said Christina Austin - CEO of Pixel Film Studios. , ... can edit the style and animation of their slideshows. Place each slide on top ...
(Date:1/15/2017)... ... ... Wondering where to go this Valentine's Day? Well, there is a solution to ... feast in the comfort of your own home. Lobster Gram is introducing two new ... until February 15th, 2017. , Romantic Dinner one is Lobster Gram's "Love at ...
Breaking Medicine News(10 mins):